These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3141056)

  • 21. Streptococcal preparation OK-432-induced interferon in human leukocytes: purification and characterization.
    De Ley M; Claeys H
    Int Arch Allergy Appl Immunol; 1984; 74(1):21-8. PubMed ID: 6423552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro.
    Sakano S; Shimabukuro T; Ohmoto Y; Naito K
    Urol Res; 1997; 25(4):239-45. PubMed ID: 9286031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [OK 432-induced production of IFN-gamma in peripheral mononuclear cells from healthy subjects and patients with cancer].
    Matsumoto H; Izutani R; Terada M; Noguchi J; Shiraha S; Kuyama T; Aoki N
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):751-8. PubMed ID: 2506311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
    Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin.
    Satoh M; Inagawa H; Shimada Y; Soma G; Oshima H; Mizuno D
    J Biol Response Mod; 1987 Oct; 6(5):512-24. PubMed ID: 2445926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines produced by blood mononuclear cells stimulated with the streptococcal preparation OK-432: effect on production by supplementing the medium with xenogeneic serum.
    Fujii M; Abo T; Kumagai K
    Cancer Immunol Immunother; 1988; 27(2):97-102. PubMed ID: 2458183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The past, the present and future of the OK-432 therapy for patients with malignant effusions.
    Katano M; Morisaki T
    Anticancer Res; 1998; 18(5D):3917-25. PubMed ID: 9854504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T; Okamoto M; Ohe G; Furuichi S; Nishikawa H; Uddin Ahmed S; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
    Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
    Ujiie T
    Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of tumor necrosis factor by administration of OK-432 in cancer patients.
    Kokunai I; Shimano T; Sekimoto K; Takeda T; Kobayashi T; Yayoi E; Yamamoto A; Mori T
    J Clin Lab Immunol; 1986 Dec; 21(4):169-71. PubMed ID: 3560194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells.
    Nio Y; Zighelboim J; Berek J; Bonavida B
    Cancer; 1989 Jul; 64(2):434-41. PubMed ID: 2736490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells].
    Katano M; Yamamoto H; Hisatsugu T
    Nihon Geka Gakkai Zasshi; 1986 Apr; 87(4):471. PubMed ID: 3713694
    [No Abstract]   [Full Text] [Related]  

  • 33. Augmentation of interleukin 1 and interleukin 2 production by OK-432.
    Ichimura O; Suzuki S; Saito M; Sugawara Y; Ishida N
    Int J Immunopharmacol; 1985; 7(2):263-70. PubMed ID: 3874175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro augmentation of natural killing activity by OK-432.
    Uchida A; Micksche M
    Int J Immunopharmacol; 1981; 3(4):365-75. PubMed ID: 6174467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of interferon-gamma and tumor necrosis factor in ascites of a patient with ovarian cancer by OK-432.
    Mori H; Itoh N; Shiraki S; Tamaya T
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):497-8. PubMed ID: 3131464
    [No Abstract]   [Full Text] [Related]  

  • 36. Production of cytotoxic factor into mouse peritoneal fluid by OK-432, a streptococcal preparation.
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Immunol Lett; 1985; 11(2):83-8. PubMed ID: 4086064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biological response modifier OK-432 (a streptococcal preparation) inhibits the development of autoimmune kidney disease in NZB/W F1 hybrid mice: possible involvement of tumor necrosis factor.
    Mihara M; Ohsugi Y
    Int Arch Allergy Appl Immunol; 1989; 90(1):37-42. PubMed ID: 2807578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF-alpha is secreted by monocytes in transit to become macrophages, but not by peripheral blood monocytes, following OK-432 (lyophilized S. pyogenes) stimulation.
    Olsnes C; Stavang H; Olofsson J; Aarstad HJ
    Scand J Immunol; 2007 Dec; 66(6):684-93. PubMed ID: 18021366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo.
    Kitsuki H; Katano M; Ikubo A; Morisaki T; Anann K; Tanaka M; Torisu M
    Clin Immunol Immunopathol; 1996 Mar; 78(3):283-90. PubMed ID: 8605704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432.
    Shitara K; Ichimura O; Mitsuno T; Osawa T
    J Immunol; 1985 Feb; 134(2):1039-47. PubMed ID: 2578148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.